0.0950CAD0.00%Mkt Cap: 30.11M CADP/E: —Last update: 2026-06-01
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap30.11M CAD
Enterprise Value118.37M CAD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-7.63M CAD
Revenue/Share—
Last Price0.0950 CAD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees—
CountryCA
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.43
PEG—
EV/EBITDA-26.00
EV/Revenue—
P/S—
P/B-0.22
EPS (TTM)-0.04
EPS (Forward)-0.22
52W Range
0.040021% of range0.3000
52W High0.3000 CAD
52W Low0.0400 CAD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE9.34%
ROA-103.96%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-3.89M CAD
CapEx (TTM)472.00K CAD
FCF Margin—
FCF Yield-12.21%
Net Debt88.25M CAD
Net Debt/EBITDA-19.39
Balance Sheet
Debt/Equity-0.20
Current Ratio0.04
Quick Ratio0.02
Book Value/Sh-0.4257 CAD
Cash/Share0.0000 CAD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 CAD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.316.98M
Float223.91M
Insiders26.40%
Institutions0.00%
Short Interest
Short Ratio1.1d
Short % Out.0.00%
Shares Short38.19K
Short (prev mo.)13.11K
Technical
SMA 500.1044 (-9.0%)
SMA 2000.1060 (-10.3%)
Beta1.04
S&P 52W Chg27.70%
Avg Vol (30d)31.17K
Avg Vol (10d)62.28K
Technical Indicators
RSI (14)38.8
MACD-0.0019
MACD Signal-0.0020
MACD Hist.+0.0001
BB Upper0.1029 CAD
BB Middle0.0993 CAD
BB Lower0.0956 CAD
BB Width7.38%
ATR (14)0.0034 CAD
Vol Ratio (20d)0.12x